Stay updated with breaking news from Aruvant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment...
/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that an abstract...
Press release content from PR Newswire. The AP news staff was not involved in its creation.
NEW YORK and BASEL, Switzerland, June 28, 2021 /PRNewswire/ -- Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced the appointment of Stanley J. Musial as chief financial officer (CFO) effective immediately. Mr. Musial brings over twenty-five years of experience building corporate value through operational execution, financial strategy and capital fundraising. "Stan's expertise in managing financials and raising capital at both private and public biotechnology companies comes at an important time as Aruvant goes through substantial g...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a potentially curative lentiviral gene therapy for sickle cell disease (SCD), will be delivered in an oral presentation at the 15th Annual Sickle Cell Disease Research & Educational Symposium & 44th National Sickle Cell Disease Scientific Meeting. Dr. Monika Asnani, professor of family medicine & epidemiology at the Caribbean Institute for Health Research, will present data from the ARU-1801 Phase 1/2 MOMENTUM clinical trial dur...